stockportfolio.pro
Harmony Biosciences Holdings, Inc. P/E Ratio 2019–2025
Harmony Biosciences Holdings, Inc. (HRMY) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -24.3%/yr over 6 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 13.81 | +0.7% |
| FY 2024 | 13.71 | -9.6% |
| FY 2023 | 15.16 | -18.3% |
| FY 2022 | 18.55 | -74.8% |
| FY 2021 | 73.52 | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
Source: Harmony Biosciences Holdings, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Harmony Biosciences Holdings, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHarmony Biosciences Holdings, Inc. — frequently asked questions
What is Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio?
Harmony Biosciences Holdings, Inc. (HRMY) reported price-to-earnings ratio of 13.81 for fiscal year 2025, per its SEC filings.
How has Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2019 and 2025, HRMY's price-to-earnings ratio declined at roughly 24.3% per year (compound annual rate), from 73.52 to 13.81.
Where does this data come from?
Figures are computed from Harmony Biosciences Holdings, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.